Gilead Sciences has responded to its growing pharma business in infectious diseases with two senior appointments.
Dr Andrew Cheng has been promoted from his current role as senior VP, HIV therapeutics and development operations to an executive VP position.
Similarly Dr Taiyin Yang is promoted from senior VP to executive VP with responsibility for pharmaceutical development and manufacturing.
Norbert Bischofberger, the company’s chief scientific officer, said: “Andrew and Taiyin have both demonstrated leadership in bringing groups together to help expedite the development and manufacturing of products – ultimately allowing the company to reach patients in need more quickly.
“These promotions recognise their achievements and dedication to bringing innovative new therapies to patients around the world.”
Dr Cheng has been with Gilead since 1999 and was appointed to his senior VP role in 2009.
Dr Yang is also a veteran of the company having joined in 1993. She was appointed senior VP in 2005.